Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lifastuzumab vedotin (DNIB0600A), an antibody-drug conjugate (ADC), consists of a humanized IgG1 monoclonal antibody targeting NaPi2b (MNIB2126A) linked to the potent antimitotic agent monomethyl auristatin E (MMAE), which disrupts cell division by inhibiting tubulin polymerization. This compound shows promise for research in non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Lifastuzumab vedotin (DNIB0600A), an antibody-drug conjugate (ADC), consists of a humanized IgG1 monoclonal antibody targeting NaPi2b (MNIB2126A) linked to the potent antimitotic agent monomethyl auristatin E (MMAE), which disrupts cell division by inhibiting tubulin polymerization. This compound shows promise for research in non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) [1]. |
Alias | DNIB0600A |
Cas No. | 1401812-88-1 |
Storage | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.